Digital Endpoints Are Coming — and Payers Need to Be Ready

Digital evidence from apps, wearables and remote sensors is already being used by medical product developers to test and measure their effectiveness. The FDA issued draft guidance earlier this year on the use of digital health technologies to acquire data remotely from clinical trial participants. And the European Medicines Agency approved its first digital endpoint, accepting one to be used to evaluate medications for Duchenne Muscular Dystrophy.

Payers are next, warned Jennifer Goldsack, CEO of the Digital Medicine Society (DiMe), speaking at the AHIP 2022 conference in Las Vegas, N.V.

© 2022 MMIT
Jill Brown Kettler

Jill Brown Kettler Executive Editor

Jill oversees AIS Health’s publications and manages the health editorial staff. She joined AIS Health in 1999, and brings unique skills and energy to the company, along with an intelligent perspective on the forces reshaping the health care industry. She holds a graduate degree in health finance and management from Johns Hopkins University School of Public Health, and was formerly a consultant with Arthur Andersen, where she worked with managed care plans, hospitals and medical groups on financial issues impacting their operations.

Related Posts

bills-and-pills
August 11

New Drug Pricing Bill Could Affect Millions of Medicare Beneficiaries

READ MORE
wall-street
August 11

In 2Q, Some PBMs Report Dampened Margins, Customer Pipelines

READ MORE
insulin-bottles
August 11

Congress Won’t Act on Insulin Prices for Commercial Market

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today